Therefore, the term 'hereditary leiomyomatosis and renal cell cancer' (HLRCC) has been replaced by 'FH-deficient renal cell carcinoma' in the WHO 2022 classification [27]. The gene discussed is FH; the disease is hereditary leiomyomatosis and renal cell cancer.